Access the full text.
Sign up today, get DeepDyve free for 14 days.
De-chao Yu, Yu Chen, Monica Seng, Jeanette Dilley, Daniel Henderson (1999)
The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.Cancer research, 59 17
S. Dhanasekaran, T. Barrette, D. Ghosh, R. Shah, S. Varambally, K. Kurachi, K. Pienta, M. Rubin, A. Chinnaiyan (2001)
Delineation of prognostic biomarkers in prostate cancerNature, 412
M. Chen, S. Lin, L. Chung, R. Sikes (1998)
Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens.The Journal of biological chemistry, 273 28
D. Banerjee (2001)
Genasense (Genta Inc).Current opinion in investigational drugs, 2 4
T. Mineta, S. Rabkin, T. Yazaki, William Hunter, R. Martuza (1995)
Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomasNature Medicine, 1
Liang Xu, W. Tang, Cheng-Cheng Huang, W. Alexander, Laiman Xiang, K. Pirollo, A. Rait, E. Chang (2001)
Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFvMolecular Medicine, 7
S. Mukherjee, T. Haenel, R. Himbeck, B. Scott, I. Ramshaw, R. Lake, G. Harnett, P. Phillips, S. Morey, D. Smith, J. Davidson, A. Musk, B. Robinson (2000)
Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generationCancer Gene Therapy, 7
S. Varghese, J. Newsome, S. Rabkin, K. McGeagh, D. Mahoney, P. Nielsen, T. Todo, R. Martuza (2001)
Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates.Human gene therapy, 12 8
M. Kawakita, G. Rao, J. Ritchey, D. Ornstein, M. Hudson, J. Tartaglia, E. Paoletti, P. Humphrey, T. Harmon, T. Ratliff (1997)
Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth.Journal of the National Cancer Institute, 89 6
Kazuhiro Suzuki, H. Nakazato, H. Matsui, M. Hasumi, Y. Shibata, Kazuto Ito, Y. Fukabori, K. Kurokawa, H. Yamanaka (2001)
NK cell‐mediated anti‐tumor immune response to human prostate cancer cell, PC‐3: immunogene therapy using a highly secretable form of interleukin‐15 gene transferJournal of Leukocyte Biology, 69
M. Steiner, C. Anthony, Yi Lu, J. Holt (1998)
Antisense c-myc retroviral vector suppresses established human prostate cancer.Human gene therapy, 9 5
Kim Chi, Martin Gleave, Richard Klasa, Nevin Murray, Cicely Bryce, Daniel Menezes, S. D’Aloisio, A. Tolcher (2001)
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 12
M. Brenner (2000)
Reports of adenovector “death” are greatly exaggerated [editorial]Mol Ther, 1
J. Douglas, B. Rogers, M. Rosenfeld, S. Michael, M. Feng, D. Curiel (1996)
Targeted gene delivery by tropism-modified adenoviral vectorsNature Biotechnology, 14
Johannes Vieweg, D. Boczkowski, K. Roberson, Darryl Edwards, M. Philip, Ramila Philip, Tracy Rudoll, Clay Smith, Cary Robertson, Eli Gilboa (1995)
Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer.Cancer research, 55 11
T. Dorai, C. Olsson, A. Katz, R. Buttyan (1997)
Development of a hammerhead ribozyme against bcl‐2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone‐refractory human prostate cancerThe Prostate, 32
D. Saffran, R. Reiter, A. Jakobovits, O. Witte (2004)
Target Antigens for Prostate Cancer ImmunotherapyCancer and Metastasis Reviews, 18
M. Morris, W. Tong, C. Cordon-Cardo, M. Drobnjak, W. Kelly, S. Slovin, K. Terry, Karen Siedlecki, P. Swanson, M. Rafi, R. DiPaola, N. Rosen, H. Scher (2002)
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 3
M. Gnant, M. Puhlmann, Alexander Hr, D. Bartlett (1999)
Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice.Cancer research, 59 14
Axel Heiser, Margaret Maurice, Donna Yancey, Ning Wu, P. Dahm, S. Pruitt, D. Boczkowski, S. Nair, M. Ballo, E. Gilboa, J. Vieweg (2001)
Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA1The Journal of Immunology, 166
S. Hall, S. Mutchnik, Guang Yang, T. Timme, Y. Nasu, C. Bangma, S. Woo, M. Shaker, T. Thompson (1999)
Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancerCancer Gene Therapy, 6
R. Rodriguez, Ho‐Yeong Lim, Lisa Bartkowski, J. Simons (1998)
Identification of diphtheria toxin via screening as a potent cell cycle and p53‐independent cytotoxin for human prostate cancer therapeuticsThe Prostate, 34
M. Gleave, H. Miyake, T. Zellweger, K. Chi, L. July, C. Nelson, P. Rennie (2001)
Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.Urology, 58 2 Suppl 1
Y. Li, J. McCadden, F. Ferrer, Mark Kruszewski, M. Carducci, J. Simons, R. Rodriguez (2002)
Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.Cancer research, 62 9
W. El-Deiry (1998)
Regulation of p53 downstream genes.Seminars in cancer biology, 8 5
F. Kruyt, D. Curiel (2002)
Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis.Human gene therapy, 13 4
T. Nakada, Y. Noguchi, S. Satoh, T. Ono, T. Saika, T. Kurashige, S. Gnjatic, G. Ritter, Yao-Tseng Chen, E. Stockert, Y. Nasu, T. Tsushima, H. Kumon, L. Old, E. Nakayama (2003)
NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer.Cancer immunity, 3
G. Murphy, B. Tjoa, S. Simmons, J. Jarisch, V. Bowes, H. Ragde, M. Rogers, A. Elgamal, G. Kenny, Oliver Cobb, R. Ireton, M. Troychak, M. Salgaller, A. Boynton (1999)
Infusion of dendritic cells pulsed with HLA‐A2‐specific prostate‐specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone‐refractory metastatic diseaseThe Prostate, 38
S. Freytag, M. Khil, H. Stricker, J. Peabody, M. Menon, M. Deperalta-Venturina, Daniel Nafziger, J. Pegg, D. Paielli, S. Brown, K. Barton, Mei Lu, E. Aguilar‐Cordova, J. Kim (2002)
Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.Cancer research, 62 17
K. Rogulski, M. Wing, D. Paielli, J. Gilbert, J. Kim, S. Freytag (2000)
Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization.Human gene therapy, 11 1
Joseph Rabinowitz, R. Samulski (2000)
Building a better vector: the manipulation of AAV virions.Virology, 278 2
I. Eder, J. Hoffmann, H. Rogatsch, G. Schäfer, D. Zopf, G. Bartsch, H. Klocker (2002)
Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptorCancer Gene Therapy, 9
S. Shariat, Smruti Desai, Weitao Song, Tahira Khan, Julie Zhao, Cuong Nguyen, Barbara Foster, Norman Greenberg, David Spencer, K. Slawin (2001)
Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.Cancer research, 61 6
N. Templeton, D. Lasič, P. Frederik, H. Strey, D. Roberts, G. Pavlakis (1997)
Improved DNA: liposome complexes for increased systemic delivery and gene expressionNature Biotechnology, 15
R. Martiniello-Wilks, Juanita Garcia-Aragon, M. Daja, Peter Russell, Gerald Both, Peter Molloy, L. Lockett, Pamela Russell (1998)
In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors.Human gene therapy, 9 11
T. Dorai, H. Perlman, K. Walsh, A. Shabsigh, E. Goluboff, C. Olsson, R. Buttyan (1999)
A recombinant defective adenoviral agent expressing anti‐bcl‐2 ribozyme promotes apoptosis of bcl‐2‐expressing human prostate cancer cellsInternational Journal of Cancer, 82
Yao-Tseng Chen, M. Scanlan, U. Şahin, O. Türeci, A. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, L. Old (1997)
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.Proceedings of the National Academy of Sciences of the United States of America, 94 5
S. Ko, A. Gotoh, G. Thalmann, H. Zhau, D. Johnston, Wei-wei Zhang, C. Kao, Leland Chung (1996)
Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.Human gene therapy, 7 14
K. Norman, M. Coffey, K. Hirasawa, D. Demetrick, S. Nishikawa, L. Difrancesco, J. Strong, Patrick Lee (2002)
Reovirus oncolysis of human breast cancer.Human gene therapy, 13 5
J. Cheon, H.K. Kim, D. Moon, D. Yoon, J.H. Cho, S. Koh (2000)
Adenovirus‐mediated suicide‐gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activityBJU International, 85
D. McNeel, L. Nguyen, M. Disis (2001)
Identification of T helper epitopes from prostatic acid phosphatase.Cancer research, 61 13
M. Puhlmann, Charles Brown, M. Gnant, James Huang, S. Libutti, H. Alexander, David Bartlett (2000)
Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutantCancer Gene Therapy, 7
T. Geiger, M. Müller, B. Monia, D. Fabbro (1997)
Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.Clinical cancer research : an official journal of the American Association for Cancer Research, 3 7
M. Serrano, G. Hannon, D. Beach (1993)
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 366
J. Moul, R. Connelly, D. Lubeck, J. Bauer, Leon Sun, S. Flanders, G. Grossfeld, Peter Carroll (2001)
Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.The Journal of urology, 166 4
Malcolm Brenner (2000)
Reports of adenovector "death" are greatly exaggerated.Molecular therapy : the journal of the American Society of Gene Therapy, 1 3
D. Gioeli, J. Mandell, G. Petroni, H. Frierson, M. Weber (1999)
Activation of mitogen-activated protein kinase associated with prostate cancer progression.Cancer research, 59 2
B. Huber, E. Austin, C. Richards, S. Davis, S. Good (1994)
Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.Proceedings of the National Academy of Sciences of the United States of America, 91 17
M. Sanda, M. Sanda, David Smith, L. Charles, C. Hwang, K. Pienta, J. Schlom, D. Milenic, D. Panicali, J. Montie (1999)
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.Urology, 53 2
S. Freytag, D. Paielli, M. Wing, K. Rogulski, S. Brown, A. Kolozsvary, J. Seely, K. Barton, A. Dragovic, J. Kim (2002)
Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model.International journal of radiation oncology, biology, physics, 54 3
N. Miller (2005)
Observations of the carrier state in hamsters infected with Leptospira interrogans serotype pomonaMedical Microbiology and Immunology, 158
M. Wilcox, W. Yang, D. Senger, N. Rewcastle, D. Morris, P. Brasher, Z. Shi, R. Johnston, S. Nishikawa, P. Lee, P. Forsyth (2001)
Reovirus as an oncolytic agent against experimental human malignant gliomas.Journal of the National Cancer Institute, 93 12
P. Sundaresan, William Hunter, R. Martuza, S. Rabkin (2000)
Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation in MiceJournal of Virology, 74
T. Burns, W. El-Deiry (1999)
The p53 pathway and apoptosisJournal of Cellular Physiology, 181
Bin Teh, Estuardo Aguilar-Cordova, Kenneth Kernen, Chieng-Chung Chou, Moshe Shalev, M. Vlachaki, Brian Miles, D. Kadmon, W. Mai, J. Caillouet, Maria Davis, Gustavo Ayala, Thomas Wheeler, Jett Brady, L. Carpenter, Hsin Lu, J. Chiu, Shiao Woo, Timothy Thompson, E. Butler (2001)
Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report.International journal of radiation oncology, biology, physics, 51 3
D. Kleinerman, Wei-wei Zhang, S. Lin, Nguyen Van, A. Eschenbach, J. Hsieh (1995)
Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study.Cancer research, 55 13
T. McDonnell, P. Troncoso, S. Brisbay, C. Logothetis, Leland Chung, J. Hsieh, S. Tu, M. Campbell (1992)
Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.Cancer research, 52 24
Nancy Thornberry, Y. Lazebnik (1998)
Caspases: enemies within.Science, 281 5381
T. Griffith, R. Anderson, B. Davidson, Richard Williams, T. Ratliff (2000)
Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis1The Journal of Immunology, 165
M. Kattan, T. Wheeler, P. Scardino (1999)
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 5
H. Kubo, T. Gardner, Y. Wada, K. Koeneman, A. Gotoh, Ling Yang, C. Kao, S. Lim, M. Amin, Hua Yang, M. Black, S. Matsubara, M. Nakagawa, J. Gillenwater, H. Zhau, L. Chung (2003)
Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.Human gene therapy, 14 3
S. Andreansky, Bin He, J. Cott, Jerry McGhee, J. Markert, G. Gillespie, Bernard Roizman, Richard Whitley (1998)
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukinsGene Therapy, 5
F.R. Steele, E. Aguilar-Cordova (2002)
Cabo II: immunology and gene therapyMol Ther, 5
T.C. Thompson, T.L. Timme, I. Sehgal (1998)
Hormones and growth factors in development and neoplasia
Jiangchun Xu, M. Kalos, J. Stolk, Eden Zasloff, Xinqun Zhang, R. Houghton, Aristides Filho, Marcos Nolasco, R. Badaró, S. Reed (2001)
Identification and characterization of prostein, a novel prostate-specific protein.Cancer research, 61 4
Jonathan Walker, Kevin McGeagh, Periasamy Sundaresan, Timothy Jorgensen, S. Rabkin, R. Martuza (1999)
Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.Human gene therapy, 10 13
M. Mehren, P. Arlen, K. Tsang, A. Rogatko, Neal Meropol, H. Cooper, M. Davey, S. McLaughlin, J. Schlom, L. Weiner (2000)
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 6
M. Marcelli, G. Cunningham, Margaret Walkup, Zening He, Lydia Sturgis, C. Kagan, R. Mannucci, I. Nicoletti, Babie Teng, L. Denner (1999)
Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer.Cancer research, 59 2
A. Belldegrun, C. Tso, A. Zisman, J. Naitoh, J. Said, A. Pantuck, A. Hinkel, J. Dekernion, R. Figlin (2001)
Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology.Human gene therapy, 12 8
I. Eder, Z. Culig, R. Ramoner, M. Thurnher, Thomas Putz, Claudia Nessler-Menardi, M. Tiefenthaler, G. Bartsch, H. Klocker (2000)
Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotidesCancer Gene Therapy, 7
E. Ben-Josef, F. Shamsa, J.D. Forman (1998)
Predicting the outcome of radiotherapy for prostate carcinoma: a model-building strategyCancer, 82
D.S. Greenberg (2000)
Stricter regulation proposed for US gene-therapy trialsLancet, 355
A. Rakhmilevich, J. Turner, Maura Ford, D. Mccabe, Wenn Sun, P. Sondel, Karen Grota, N. Yang (1996)
Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors.Proceedings of the National Academy of Sciences of the United States of America, 93 13
D. Yu, G. Sakamoto, D. Henderson (1999)
Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.Cancer research, 59 7
Hajime Higuchi, S. Bronk, Andrew Bateman, Kevin Harrington, R. Vile, G. Gores (2000)
Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.Cancer research, 60 22
F. Sirotnak, L. Sepp-Lorenzino, N. Kohl, N. Rosen, H. Scher (2000)
A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utilityCancer Chemotherapy and Pharmacology, 46
M. Sanford, Y. Yan, S. Canfield, W. Hassan, W. Selleck, G. Atkinson, S. Chen, S. Hall (2001)
Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer.Human gene therapy, 12 12
Lieping Chen, S. Ashe, W. Brady, I. Hellström, K. Hellström, J. Ledbetter, P. Mcgowan, P. Linsley (1992)
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4Cell, 71
M. Steiner, Xiongwen Zhang, Ying Wang, Yi Lu (2000)
Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde.Cancer research, 60 16
J. Eastham, Shu-Hsia Chen, I. Sehgal, Guang Yang, T. Timme, S. Hall, S. Woo, T. Thompson (1996)
Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.Human gene therapy, 7 4
J. Eastham, S. Hall, hider Sehgal, Jianxiang Wang, T. Timme, Guang Yang, Lisa Connell‐Crowley, S. Elledge, Wei-wei Zhang, J. Harper, T. Thompson (1995)
In vivo gene therapy with p53 or p21 adenovirus for prostate cancer.Cancer research, 55 22
Francesca Andriani, Bicheng Nan, Jiang Yu, Xiaoying Li, N. Weigel, M. McPhaul, Susan Kasper, Shunsuke Kagawa, Bingliang Fang, R. Matusik, Larry Denner, Marco Marcelli (2001)
Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.Journal of the National Cancer Institute, 93 17
Moshe Shalev, D. Kadmon, Bin Teh, E. Butler, Estuardo Aguilar-Cordova, Timothy Thompson, James Herman, Howard Adler, P. Scardino, Brian Miles (2000)
Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.The Journal of urology, 163 6
A. Uchida, D. O’Keefe, D. Bacich, P. Molloy, W. Heston (2001)
In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.Urology, 58 2 Suppl 1
Z. Ram, S. Walbridge, Thomas Shawker, K. Culver, R. Blaese, E. Oldfield (1994)
The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats.Journal of neurosurgery, 81 2
S. Lowe, S. Rubinchik, T. Honda, T. McDonnell, J-y Dong, J. Norris (2001)
Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cellsGene Therapy, 8
J.W. Harper (1997)
Cyclin dependent kinase inhibitorsCancer Surv, 29
Wenn Sun, J. Burkholder, Jian-ying Sun, Jerilyn Culp, J. Turner, Xing Lu, T. Pugh, W. Ershler, N. Yang (1995)
In vivo cytokine gene transfer by gene gun reduces tumor growth in mice.Proceedings of the National Academy of Sciences of the United States of America, 92
L. Fong, C. Ruegg, D. Brockstedt, E. Engleman, R. Laus (1997)
Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer.Journal of immunology, 159 7
Misop Han, A. Partin (2002)
Nomograms for clinically localized prostate cancer. Part I: radical prostatectomy.Seminars in urologic oncology, 20 2
L. Benimetskaya, P. Miller, Simon Benimetsky, A. Maciaszek, P. Guga, S. Beaucage, A. Wilk, A. Grajkowski, Anthony Halperin, C. Stein (2001)
Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.Molecular pharmacology, 60 6
L. Fong, D. Brockstedt, C. Benike, Jami Breen, G. Strang, C. Ruegg, E. Engleman (2001)
Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy1The Journal of Immunology, 167
D. Paielli, M. Wing, K. Rogulski, J. Gilbert, A. Kolozsvary, J. Kim, J. Hughes, M. Schnell, T. Thompson, S. Freytag (2000)
Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.Molecular therapy : the journal of the American Society of Gene Therapy, 1 3
Jiangchun Xu, J. Stolk, Xinqun Zhang, Sandra Silva, Raymond Houghton, Masazumi Matsumura, T. Vedvick, Kevin Leslie, Roberto Badaró, Steven Reed (2000)
Identification of differentially expressed genes in human prostate cancer using subtraction and microarray.Cancer research, 60 6
A. Melcher, S. Todryk, N. Hardwick, M. Ford, M. Jacobson, R. Vile (1998)
Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expressionNature Medicine, 4
W. Parker, S. King, P. Allan, L. Bennett, J. Secrist, J. Montgomery, Karen Gilbert, W. Waud, A. Wells, G. Gillespie, E. Sorscher (1997)
In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.Human gene therapy, 8 14
Won Kang, Chaehwa Park, Hyunah Yoon, Won Kim, Sung-Soo Yoon, Mark Lee, Keunchil Park, Ki-Hyun Kim, H. Jeong, Jeong-A Kim, Jeong-A Kim, Seok-Jin Nam, Jung-Hyun Yang, Young-Ik Son, Chung-Hwan Baek, Jung Han, Howe Ree, Eil Lee, Sun-Hee Kim, Dae Kim, Yong Ahn, S. Huh, Yeon Choe, Je-Ho Lee, M. Park, Gyoung-Sun Kong, Eun Park, Yoon-Koo Kang, Yung-Jue Bang, Nam-Sun Paik, Soon Lee, Seon Kim, Sunyoung Kim, Paul Robbins, Hideaki Tahara, M. Lotze, Chan-Hoo Park (2001)
Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study.Human gene therapy, 12 6
W. Kelly, S. Slovin (2000)
Chemotherapy for androgenindependent prostate cancer: Myth or realityCurrent Oncology Reports, 2
K. Koeneman, C. Kao, S. Ko, Ling Yang, Y. Wada, D. Kallmes, J. Gillenwater, H. Zhau, L. Chung, T. Gardner (2000)
Osteocalcin-directed gene therapy for prostate-cancer bone metastasisWorld Journal of Urology, 18
P. Smaglik (2000)
NIH tightens up monitoring of gene-therapy mishapsNature, 404
A. Gotoh, C. Kao, S. Ko, K. Hamada, T. Liu, L. Chung (1997)
Cytotoxic Effects of Recombinant Adenovirus p53 and Cell Cycle Regulator Genes (p21 sup WAF1/CIP1 and p16 sup CDKN4) in Human Prostate CancersThe Journal of Urology, 158
I. Dmitriev, V. Krasnykh, C. Miller, Minghui Wang, E. Kashentseva, Galina Mikheeva, N. Belousova, D. Curiel (1998)
An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry MechanismJournal of Virology, 72
Andrew Bateman, Francis Bullough, Stephen Murphy, L. Emiliusen, Dimitri Lavillette, F. Cosset, Roberto Cattaneo, Stephen Russell, R. Vile (2000)
Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth.Cancer research, 60 6
E. Small, Paige Fratesi, D. Reese, G. Strang, R. Laus, M. Peshwa, F. Valone (2000)
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 23
P. Burch, Jami Breen, J. Buckner, D. Gastineau, Judith Kaur, R. Laus, D. Padley, M. Peshwa, H. Pitot, R. Richardson, Bouwien Smits, Pitsata Sopapan, G. Strang, F. Valone, S. Vuk-Pavlović (2000)
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 6
R. Ramesh, A. Marrogi, A. Munshi, C. Abboud, S. Freeman (1996)
In vivo analysis of the 'bystander effect': a cytokine cascade.Experimental hematology, 24 7
Xiaoying Li, M. Marani, Jiang Yu, Bicheng Nan, J. Roth, Shunsuke Kagawa, Bingliang Fang, Larry Denner, Marco Marcelli (2001)
Adenovirus-mediated Bax overexpression for the induction of therapeutic apoptosis in prostate cancer.Cancer research, 61 1
D. Greenberg (2000)
WASHINGTON Stricter regulation proposed for US gene-therapy trialsThe Lancet, 355
R. Blackburn, S. Galoforo, P. Corry, Y. Lee (1999)
Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivityInternational Journal of Cancer, 82
S. Lin, Y. Pu (1999)
Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer.Seminars in oncology, 26 2
J. Merritt, J. Roth, C. Logothetis (2001)
Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies.Seminars in oncology, 28 5 Suppl 16
Michael Mastrangelo, Laurence Eisenlohr, Leonard Gomella, Edmund Lattime (2000)
Poxvirus vectors: orphaned and underappreciated.The Journal of clinical investigation, 105 8
T. Timme, S. Hall, R. Barrios, S. Woo, E. Aguilar‐Cordova, T. Thompson (1998)
Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.Cancer gene therapy, 5 2
P. Huber, P. Huber, P. Huber, P. Pfisterer, P. Pfisterer (2000)
In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasoundGene Therapy, 7
S. Freytag, H. Stricker, J. Pegg, D. Paielli, D. Pradhan, J. Peabody, M. Deperalta-Venturina, X. Xia, S. Brown, Mei Lu, J. Kim (2003)
Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.Cancer research, 63 21
E. Ben-Josef, F. Shamsa, J. Forman (1998)
Predicting the outcome of radiotherapy for prostate carcinomaCancer, 82
David Barba, J. Hardin, M. Sadelain, F. Gage (1994)
Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors.Proceedings of the National Academy of Sciences of the United States of America, 91 10
J. Leonard, M. Sherman, G. Fisher, L. Buchanan, G. Larsen, M. Atkins, J. Sosman, J. Dutcher, N. Vogelzang, J. Ryan (1997)
Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ ProductionBlood, 90
J. Allay, M. Steiner, Yu Zhang, Christopher Reed, Jody Cockroft, Yi Lu (2000)
Adenovirus p16 gene therapy for prostate cancerWorld Journal of Urology, 18
K. Balaji, H. Koul, S. Mitra, Carlos Maramag, Premveer Reddy, M. Menon, R. Malhotra, Seethalaksmi Laxmanan (1997)
Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer.Urology, 50 6
T. DeWeese, H. Poel, Shidong Li, B. Mikhak, R. Drew, M. Goemann, U. Hamper, R. DeJong, N. Detorie, R. Rodriguez, T. Haulk, A. DeMarzo, S. Piantadosi, De-chao Yu, Yu Chen, Daniel Henderson, M. Carducci, W. Nelson, J. Simons (2001)
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.Cancer research, 61 20
J. Eder, P. Kantoff, K. Roper, G. Xu, G. Bubley, J. Boyden, L. Gritz, G. Mazzara, W. Oh, P. Arlen, K. Tsang, D. Panicali, J. Schlom, D. Kufe (2000)
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 5
H. Terasawa, K. Tsang, J. Gulley, P. Arlen, J. Schlom (2002)
Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 1
James Wilson (1996)
Adenoviruses as gene-delivery vehicles.The New England journal of medicine, 334 18
M. Sanda, M. Sanda, Sujatha Ayyagari, Sujatha Ayyagari, Elizabeth Jaffee, Elizabeth Jaffee, Jonathan Epstein, Jonathan Epstein, S. Clift, S. Clift, Lawrence Cohen, Lawrence Cohen, Glenn Dranoff, Glenn Dranoff, Drew Pardoll, Drew Pardoll, Richard Mulligan, Richard Mulligan, J. Simons, J. Simons (1994)
Demonstration of a rational strategy for human prostate cancer gene therapy.The Journal of urology, 151 3
T. Dorai, Goluboff Et, C. Olsson, R. Buttyan (1997)
Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents.Anticancer research, 17 5A
Y. Nasu, C. Bangma, G. Hull, Guang Yang, Jianxiang Wang, S. Shimura, Mark McCurdy, S. Ebara, Hon-Man Lee, T. Timme, T. Thompson (2001)
Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancerProstate Cancer and Prostatic Diseases, 4
J. Markert, Medlock, SD Rabkin, G. Gillespie, T. Todo, William Hunter, C. Palmer, F. Feigenbaum, C. Tornatore, F. Tufaro, R. Martuza (2000)
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Therapy, 7
Paul Robbins, S. Ghivizzani (1998)
Viral vectors for gene therapy.Pharmacology & therapeutics, 80 1
Jerry Adams, S. Cory (1998)
The Bcl-2 protein family: arbiters of cell survival.Science, 281 5381
M. Magnusson, Saw Hong, Petra Henning, P. Boulanger, L. Lindholm (2002)
Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viabilityThe Journal of Gene Medicine, 4
M. Coffey, James Strong, P. Forsyth, Patrick Lee (1998)
Reovirus therapy of tumors with activated Ras pathway.Science, 282 5392
Liang Xu, K. Pirollo, Wenhua Tang, A. Rait, E. Chang (1999)
Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts.Human gene therapy, 10 18
P. Correale, K. Walmsley, S. Zaremba, M. Zhu, J. Schlom, K. Tsang (1998)
Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.Journal of immunology, 161 6
G. Ayala, T. Wheeler, M. Shalev, T. Thompson, B. Miles, E. Aguilar‐Cordova, S. Chakraborty, D. Kadmon (2000)
Cytopathic effect of in situ gene therapy in prostate cancer.Human pathology, 31 7
P. Ross, C. Gerigk, M. Gonen, O. Yossepowitch, I. Cagiannos, P. Sogani, P. Scardino, M. Kattan (2002)
Comparisons of nomograms and urologists' predictions in prostate cancer.Seminars in urologic oncology, 20 2
P. Correale, L. Micheli, M. Vecchio, M. Sabatino, R. Petrioli, D. Pozzessere, S. Marsili, G. Giorgi, L. Lozzi, P. Neri, G. Francini (2001)
A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2British Journal of Cancer, 85
K. Pirollo, L. Xu, E. Chang (2000)
Non-viral gene delivery for p53.Current opinion in molecular therapeutics, 2 2
W. Isaacs, G. Bova, R. Morton, M. Bussemakers, J. Brooks, C. Ewing (1994)
Molecular biology of prostate cancer.Seminars in oncology, 21 5
S. Ponnazhagan, David Curiel, Denise Shaw, R. Alvarez, G. Siegal (2001)
Adeno-associated virus for cancer gene therapy.Cancer research, 61 17
D. Jarrard, G. Bova, C. Ewing, Sokhom Pin, S. Nguyen, S. Baylin, P. Cairns, D. Sidransky, J. Herman, W. Isaacs (1997)
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancerGenes, 19
A. Heiser, Doris Coleman, J. Dannull, Donna Yancey, Margaret Maurice, C. Lallas, P. Dahm, D. Niedzwiecki, E. Gilboa, J. Vieweg (2002)
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.The Journal of clinical investigation, 109 3
Xiaoming Xie, Xiuqin Zhao, Yuanfang Liu, Jianfeng Zhang, R. Matusik, K. Slawin, David Spencer (2001)
Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.Cancer research, 61 18
M. Kashani-Sabet, Scanlon Kj (1995)
Application of ribozymes to cancer gene therapy.Cancer gene therapy, 2 3
K. Hirasawa, S. Nishikawa, K. Norman, T. Alain, A. Kossakowska, Patrick Lee (2002)
Oncolytic reovirus against ovarian and colon cancer.Cancer research, 62 6
W. Bi, L. Parysek, R. Warnick, P. Stambrook (1993)
In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy.Human gene therapy, 4 6
D. Latchman (2001)
Gene delivery and gene therapy with herpes simplex virus-based vectors.Gene, 264 1
S. Zhang, H. Zhang, V. Reuter, S. Slovin, H. Scher, P. Livingston (1998)
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers.Clinical cancer research : an official journal of the American Association for Cancer Research, 4 2
R. Martiniello-Wilks, T. Tsatralis, P. Russell, D. Brookes, D. Zandvliet, L. Lockett, G. Both, P. Molloy, P. Russell (2002)
Transcription-targeted gene therapy for androgen-independent prostate cancerCancer Gene Therapy, 9
M. Chhikara, M. Chhikara, Hanxian Huang, Hanxian Huang, M. Vlachaki, Xiaohong Zhu, B. Teh, K. Chiu, S. Woo, B. Berner, E. Smith, K. Oberg, K. Oberg, L. Aguilar, T. Thompson, E. Butler, E. Aguilar‐Cordova (2001)
Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer.Molecular therapy : the journal of the American Society of Gene Therapy, 3 4
Brian Miles, Moshe Shalev, Estuardo Aguilar-Cordova, T. Timme, Hon-Man Lee, Guang Yang, Howard Adler, Kenneth Kernen, C. Pramudji, Takefumi Satoh, Y. Gdor, Chengzhen Ren, Gustavo Ayala, Thomas Wheeler, E. Butler, D. Kadmon, Timothy Thompson (2001)
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy.Human gene therapy, 12 16
K. Rogulski, J. Kim, Sang Kim, S. Freytag (1997)
Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity.Human gene therapy, 8 1
Y. Nasu, C. Bangma, G. Hull, Hon-Man Lee, J. Hu, Jianxiang Wang, Mark McCurdy, S. Shimura, Guang Yang, T. Timme, T. Thompson (1999)
Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic modelGene Therapy, 6
M. Chase, Richard Chung, E. Chiocca (1998)
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapyNature Biotechnology, 16
Christopher Logg, Chien-Kuo Tai, Aki Logg, W. Anderson, Noriyuki Kasahara (2001)
A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors.Human gene therapy, 12 8
Templeton Ns (2001)
Developments in liposomal gene delivery systemsExpert Opinion on Biological Therapy, 1
A. Levine (1997)
p53, the Cellular Gatekeeper for Growth and DivisionCell, 88
S. Freytag, K. Rogulski, D. Paielli, J. Gilbert, J. Kim (1998)
A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy.Human gene therapy, 9 9
Barbara Nasto (2002)
Questions about systemic adenovirus delivery.Molecular therapy : the journal of the American Society of Gene Therapy, 5 6
G. Atkinson, S. Hall (1999)
Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer.Urology, 54 6
S. Hall, S. Mutchnik, Shu-Hsia Chen, S. Woo, T. Thompson (1997)
Adenovirus‐mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancerInternational Journal of Cancer, 70
M. Steiner, Yu Zhang, F. Farooq, J. Lerner, Ying Wang, Yi Lu (2000)
Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescenceCancer Gene Therapy, 7
C. Pramudji, S. Shimura, S. Ebara, G. Yang, J. Wang, C. Ren, Y. Yuan, S. Tahir, T. Timme, T. Thompson (2001)
In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 12
Takashi Okada, M. Shah, James Higginbotham, Q. Li, Oliver Wildner, S. Walbridge, Edward Oldfield, R. Blaese, W. Ramsey (2001)
AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor depositsGene Therapy, 8
William Hunter, William Hunter, R. Martuza, F. Feigenbaum, T. Todo, Toshihiro Mineta, Toshihiro Mineta, T. Yazaki, M. Toda, J. Newsome, R. Platenberg, H. Manz, S. Rabkin (1999)
Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman PrimatesJournal of Virology, 73
N. Rainov, C. Kramm, U. Banning, D. Riemann, H. Holzhausen, V. Heidecke, K. Burger, W. Burkert, D. Körholz (2000)
Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiformeGene Therapy, 7
G. Hull, Mark McCurdy, Y. Nasu, C. Bangma, Guang Yang, S. Shimura, Hon-Man Lee, Jianxiang Wang, Justin Albani, S. Ebara, Takefumi Sato, T. Timme, T. Thompson (2000)
Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 10
J. Simons, B. Mikhak, Ju-Fay Chang, A. DeMarzo, M. Carducci, M. Lim, C. Weber, A. Baccala, M. Goemann, S. Clift, D. Ando, H. Levitsky, L. Cohen, M. Sanda, R. Mulligan, A. Partin, H. Carter, S. Piantadosi, F. Marshall, W. Nelson (1999)
Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.Cancer research, 59 20
N. Meidenbauer, D. Harris, L. Spitler, T. Whiteside (2000)
Generation of PSA‐reactive effector cells after vaccination with a PSA‐based vaccine in patients with prostate cancerThe Prostate, 43
Duan Yu, Dalin Chen, Chris Chiu, Babak Razmazma, Y. Chow, S. Pang (2001)
Prostate-specific targeting using PSA promoter-based lentiviral vectorsCancer Gene Therapy, 8
S. Lin, Y. Pu, W. Luo, Y. Wang, C. Logothetis (1999)
Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model.Anticancer research, 19 1A
H. Miyake, I. Hara, S. Kamidono, M. Gleave (2001)
Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti‐apoptotic genes upregulated after androgen withdrawal to delay androgen‐independent progression and enhance chemosensitivityInternational Journal of Urology, 8
J. Fortner, J. Rhoads (1987)
Accomplishments in cancer research. 1986
James Herman, Howard Adler, Estuardo Aguilar-Cordova, Augusto Rojas-Martinez, S. Woo, T. Timme, Thomas Wheeler, Thomas Wheeler, Timothy Thompson, P. Scardino (1999)
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.Human gene therapy, 10 7
C. Springer, I. Niculescu-Duvaz (2000)
Prodrug-activating systems in suicide gene therapy.The Journal of clinical investigation, 105 9
Liang Xu, P. Frederik, K. Pirollo, Wen-hua Tang, A. Rait, Laiman Xiang, Weiqun Huang, I. Cruz, Yuzhi Yin, E. Chang (2002)
Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery.Human gene therapy, 13 3
R. Rodriguez, E. Schuur, Ho Lim, Gail Henderson, J. Simons, Daniel Henderson (1997)
Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.Cancer research, 57 13
R. Dickson, D. Salomon (1998)
Hormones and growth factors in development and neoplasia Edited by Robert B. Dickson and David S. Salomon. Wiley-Liss Inc., New York, 1998, 461 pp. ISBN: 0-471-16899-8, £80.95The Journal of Steroid Biochemistry and Molecular Biology, 67
A.D. Miller (1992)
Retroviral vectorsCurr Top Microbiol Immunol, 158
S. Advani, Su-Mi Chung, Sze Yan, G. Gillespie, J. Markert, Richard Whitley, Bernard Roizman, Ralph Weichselbaum (1999)
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors.Cancer research, 59 9
N. Vogelzang (1996)
Comprehensive Textbook of Genitourinary Oncology
J. Yu, S. DeRuiter, D. Turner (2002)
RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cellsProceedings of the National Academy of Sciences of the United States of America, 99
E. Galanis, A. Bateman, Kimberly Johnson, R. Díaz, C. James, R. Vile, Stephen Russell (2001)
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.Human gene therapy, 12 7
B. Vogelstein, K. Kinzler (1992)
p53 function and dysfunctionCell, 70
H. Miyake, Kim Chi, Martin Gleave (2000)
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 5
Chun‐Hung Yang, C. Cirielli, M. Capogrossi, A. Passaniti (1995)
Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells.Cancer research, 55 19
Chung Td, H. Mauceri, Dennis Hallahan, Yu Jj, S. Chung, Grdina Wl, S. Yajnik, Donald Kufe, Ralph Weichselbaum (1998)
Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer.Cancer gene therapy, 5 6
T. Curiel, D. Curiel (2002)
Tumor immunotherapy: inching toward the finish line.The Journal of clinical investigation, 109 3
E. Galanis, R. Vile, S. Russell (2001)
Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors.Critical reviews in oncology/hematology, 38 3
R. Anello, S. Cohen, G. Atkinson, S. Hall (2000)
Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation.The Journal of urology, 164 6
Gene therapy for prostate cancer is a relatively new experimental treatment modality and several different therapeutic approaches are being considered. Prostate cancer is the most commonly diagnosed cancer in males and has unique features that make it ideal for gene therapy. Although prostate cancer that is confined to the gland can be cured in many of the patients using local treatments (radical prostatectomy or irradiation therapy), the long-term failure rate of these therapies suggests that cancers can metastasize relatively early in the course of the disease. Once prostate cancer has metastasized there are no curative therapies. The greatest challenge in the treatment of advanced prostate cancer is to access and eliminate metastatic cells. Therefore, successful prostate cancer gene therapy will ultimately require an effective strategy to kill cancer cells both at the site of the primary tumor and at distant metastatic sites.
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.